RECRUITING

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Description

This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.

Conditions

Cardiovascular DisorderClonal HematopoiesisHodgkin Lymphoma
Talk to us

Related Conditions:

Cardiovascular DisorderClonal HematopoiesisHodgkin Lymphoma

Study Overview

On this page

Study Details

Study overview

This study assesses how blood cell growth patterns (clonal hematopoiesis), relates to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.

Assessment of Clonal Hematopoiesis and Its Relationship to Cardiovascular Disease in Hodgkin Lymphoma Survivors

A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma

Condition
Cardiovascular Disorder
Intervention / Treatment

-

Contacts and Locations

Mobile

USA Health Strada Patient Care Center, Mobile, Alabama, United States, 36604

Phoenix

Phoenix Childrens Hospital, Phoenix, Arizona, United States, 85016

Wilmington

Alfred I duPont Hospital for Children, Wilmington, Delaware, United States, 19803

Fort Myers

Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States, 33908

Tampa

Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States, 33607

Ann Arbor

C S Mott Children's Hospital, Ann Arbor, Michigan, United States, 48109

Minneapolis

Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States, 55404

Saint Louis

Washington University School of Medicine, Saint Louis, Missouri, United States, 63110

Hackensack

Hackensack University Medical Center, Hackensack, New Jersey, United States, 07601

Albany

Albany Medical Center, Albany, New York, United States, 12208

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient must be \>= 7 years of age at the time of enrollment (age to perform an MRI without sedation).
  • * Enrolled and completed therapy on AHOD1331.
  • * Not known to have had a primary event (relapse/second malignancy/death). Note: Subjects enrolled and/or treated on AHOD1331 at another institution are eligible if they are now being followed at the current Children's Oncology Group (COG) institution.
  • * Patient must have access to cardiac MRI at institution where receiving follow-up care and must be able to complete cardiac MRI without sedation.
  • * All patients and/or their parents or legal guardians must sign a written informed consent.
  • * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
  • * Medical contraindication to undergoing a cardiac MRI.
  • * Removed from AHOD1331 therapy prior to completing the AHOD1331 protocol specified treatment plan.
  • * Received cancer therapy in addition to that of AHOD1331 (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).
  • * History of cardiovascular disease prior to enrollment on AHOD1331.

Ages Eligible for Study

7 Years to 40 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Children's Oncology Group,

Robert J Hayashi, PRINCIPAL_INVESTIGATOR, Children's Oncology Group

Study Record Dates

2028-10-01